RET-HE
Investigating the Value of Reticulocyte Haemoglobin Content (RET-he) in the Management of Functional Martial Deficiency Anaemia in Patients With Solid Tumours
Sponsor study identifier
observational
51
1 country
1
Study Start
May 4, 2017
Actual (reported)Primary Completion
May 11, 2020
Actual (reported)Study Completion
May 11, 2020
Actual (reported)Determine the value of the initial measurement of the hemoglobin content of reticulocytes (RET-He) for predicting the response to martial treatment for patients with a solid tumor with a functional martial deficiency as defined NCCN2016 (with or without inflammation). The aim is to refine the current definition of functional martial deficiency in order to best adapt the iron prescription in oncology by giving iron only if necessary, i.e. if the RET is low.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 11, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 4, 2017
Actual (reported)August 28, 2018
Actual (reported)September 4, 2018
Actual (reported)May 11, 2020
Actual (reported)May 11, 2020
Actual (reported)August 17, 2026
Actual (reported)Spearman Correlation Coefficient Between RET-He at Baseline and Hemoglobin at 1 Month After Intravenous Iron Treatment
Spearman correlation between RET-He measured at baseline (initial blood test) and hemoglobin level measured 1 month after intravenous iron treatment.
1 month after inclusion
Percentage of Participants With Hemoglobin Increase ≥1 g/dL 1 Month After Intravenous Iron Treatment (With or Without Erythropoiesis-stimulating Agent)
1 month
Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
Haemoglobin measure before and one month after standard iron treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adult patients with anaemia treated at the ICO for a solid tumour, not treated or treated with chemotherapy and/or radiotherapy and/or surgery, having benefited before the inclusion of a blood test including an NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH.
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44805, France
Mathilde DUPE, MD
Institut de Cancérologie de l'Ouest
51 participants (actual enrollment reported by the registry).
First Submitted
August 28, 2018
First Posted
September 4, 2018
Study Start
May 4, 2017
Actual (reported)A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer
Contact the study team to confirm eligibility.
Primary Completion
May 11, 2020
Actual (reported)Study Completion
May 11, 2020
Actual (reported)Last Updated
August 17, 2026
Results First Posted
August 17, 2026
Record last verified: 2021-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: